FARON PHARMACEUTICALS OY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127.5 GBX | 0.00% |
|
+8.51% | -58.20% |
| Apr. 16 | Faron Pharmaceuticals Oy Confirms Plans for the Coming Months | CI |
| Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Presenter SpeechMarkku Jalkanen (Executives)Good morning, everyone. My name is Markku Jalkanen...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faronâs drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.
Calendar
2024-08-26
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.488
EUR
Average target price
11.6
EUR
Spread / Average Target
+680.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.20% | 114M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- FARN Stock
- News Faron Pharmaceuticals Oy
- Transcript : Faron Pharmaceuticals Oy - Special Call
